Alterations in mouse Hypothalamic adipokine gene expression and leptin signaling following chronic spinal cord injury and with advanced age

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Bigford, Gregory E ^a   Bracchi Ricard, Valerie C ^a   Nash, Mark S ^a   Bethea, John R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; FASTING INDUCED ADIPOSE FACTOR; JANUS KINASE 2; JANUS KINASE 3; LEPTIN; LONG FORM LEPTIN RECEPTOR; PROTEIN IRE1; PROTEIN PERK; RESTIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF2ALPHA; UNCLASSIFIED DRUG; UNCOUPLED PROTEIN RESPONSE;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; FEMALE; FIAF GENE; GENE; GENE EXPRESSION; HYPOTHALAMUS; INFLAMMATION; LEPRB GENE; MOUSE; NEUROENDOCRINE DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RSTN GENE; SIGNAL TRANSDUCTION; SOCS3 GENE; SPINAL CORD INJURY;

ADIPOKINES; AGING; ANGIOPOIETINS; ANIMALS; EIF-2 KINASE; EUKARYOTIC INITIATION FACTOR-2; FEMALE; GENE EXPRESSION REGULATION; HYPOTHALAMUS; INFLAMMATION; LEPTIN; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, LEPTIN; RESISTIN; SIGNAL TRANSDUCTION; SPINAL CORD INJURIES; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84863993433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041073     Document Type: Article

References (124)

1. Fehlings LSaM, (2001) Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine 26: S2-12.
2. Fehlings WJaM, (2003) The molecular basis of neural regeneration. Neurosurgery 53: 943-948.
3. Cadotte DW, Fehlings MG, (2011) Spinal cord injury: a systematic review of current treatment options. Clin Orthop Relat Res 469: 732-741.
4. Maayken van den Berg JMC, Jesus de Pedro-Cuesta, Ignacia Mahillo-Fernandez, (2010) Survival after Spinal Cord Injury: A systematic Review. Journal of Neurotrauma 27: 1517-1528.
5. Ahn H, Fehlings MG, (2008) Prevention, identification, and treatment of perioperative spinal cord injury. Neurosurg Focus 25: E15.
6. Wahman K, Nash MS, Lewis JE, Seiger A, Levi R, (2011) Cardiovascular disease risk and the need for prevention after paraplegia determined by conventional multifactorial risk models: the Stockholm spinal cord injury study. J Rehabil Med 43: 237-242.
7. Bauman WA, Spungen AM, Adkins RH, Kemp BJ, (1999) Metabolic and endocrine changes in persons aging with spinal cord injury. Assist Technol 11: 88-96.
8. DeVivo MJ, Krause JS, Lammertse DP, (1999) Recent trends in mortality and causes of death among persons with spinal cord injury. Arch Phys Med Rehabil 80: 1411-1419.
9. Garshick E, Kelley A, Cohen SA, Garrison A, Tun CG, et al. (2005) A prospective assessment of mortality in chronic spinal cord injury. Spinal Cord 43: 408-416.
10. Myers J, Lee M, Kiratli J, (2007) Cardiovascular disease in spinal cord injury: an overview of prevalence, risk, evaluation, and management. Am J Phys Med Rehabil 86: 142-152.
11. Nash MS, Mendez AJ, (2007) A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia. Arch Phys Med Rehabil 88: 751-757.
12. Spungen AM, Adkins RH, Stewart CA, Wang J, Pierson RN Jr, et al. (2003) Factors influencing body composition in persons with spinal cord injury: a cross-sectional study. J Appl Physiol 95: 2398-2407.
13. Gorgey AS, Gater DR, (2011) A preliminary report on the effects of the level of spinal cord injury on the association between central adiposity and metabolic profile. PM R 3: 440-446.
14. Liang H, Chen D, Wang Y, Rimmer JH, Braunschweig CL, (2007) Different risk factor patterns for metabolic syndrome in men with spinal cord injury compared with able-bodied men despite similar prevalence rates. Arch Phys Med Rehabil 88: 1198-1204.
15. Groah SL, Nash MS, Ljungberg IH, Libin A, Hamm LF, et al. (2009) Nutrient intake and body habitus after spinal cord injury: an analysis by sex and level of injury. J Spinal Cord Med 32: 25-33.
16. Brenes G, Dearwater S, Shapera R, LaPorte RE, Collins E, (1986) High density lipoprotein cholesterol concentrations in physically active and sedentary spinal cord injured patients. Arch Phys Med Rehabil 67: 445-450.
17. Bauman WA, Spungen AM, Zhong YG, Rothstein JL, Petry C, et al. (1992) Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury. Paraplegia 30: 697-703.
18. Zlotolow SP, Levy E, Bauman WA, (1992) The serum lipoprotein profile in veterans with paraplegia: the relationship to nutritional factors and body mass index. J Am Paraplegia Soc 15: 158-162.
19. Karlsson AK, Attvall S, Jansson PA, Sullivan L, Lonnroth P, (1995) Influence of the sympathetic nervous system on insulin sensitivity and adipose tissue metabolism: a study in spinal cord-injured subjects. Metabolism 44: 52-58.
20. Maki KC, Briones ER, Langbein WE, Inman-Felton A, Nemchausky B, et al. (1995) Associations between serum lipids and indicators of adiposity in men with spinal cord injury. Paraplegia 33: 102-109.
21. McGlinchey-Berroth R, Morrow L, Ahlquist M, Sarkarati M, Minaker KL, (1995) Late-life spinal cord injury and aging with a long term injury: characteristics of two emerging populations. J Spinal Cord Med 18: 183-193.
22. Bauman WA, Kahn NN, Grimm DR, Spungen AM, (1999) Risk factors for atherogenesis and cardiovascular autonomic function in persons with spinal cord injury. Spinal Cord 37: 601-616.
23. Bauman WA, Spungen AM, Raza M, Rothstein J, Zhang RL, et al. (1992) Coronary artery disease: metabolic risk factors and latent disease in individuals with paraplegia. Mt Sinai J Med 59: 163-168.
24. Washburn RA, Figoni SF, (1999) High density lipoprotein cholesterol in individuals with spinal cord injury: the potential role of physical activity. Spinal Cord 37: 685-695.
25. Bauman WA, Spungen AM, (2001) Carbohydrate and lipid metabolism in chronic spinal cord injury. J Spinal Cord Med 24: 266-277.
26. Nash MS, Lewis JE, Dyson-Hudson TA, Szlachcic Y, Yee F, et al. (2011) Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial. Arch Phys Med Rehabil 92: 399-410.
27. Bauman WA, Spungen AM, (1994) Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging. Metabolism 43: 749-756.
28. Kemp BJ, (2005) What the rehabilitation professional and the consumer need to know. Phys Med Rehabil Clin N Am 16: 1-18, vii.
29. Charlifue S, Jha A, Lammertse D, (2010) Aging with spinal cord injury. Phys Med Rehabil Clin N Am 21: 383-402.
30. Groah SL, Charlifue S, Tate D, Jensen MP, Molton IR, et al. (2012) Spinal cord injury and aging: challenges and recommendations for future research. Am J Phys Med Rehabil 91: 80-93.
31. Hitzig SL, Eng JJ, Miller WC, Sakakibara BM, Team SR (2011) An evidence-based review of aging of the body systems following spinal cord injury. Spinal Cord 49: 684-701.
32. Ahima RS, Qi Y, Singhal NS, Jackson MB, Scherer PE, (2006) Brain adipocytokine action and metabolic regulation. Diabetes 55: S145-154.
33. Ahima RS, Qi Y, Singhal NS, (2006) Adipokines that link obesity and diabetes to the hypothalamus. Prog Brain Res 153: 155-174.
34. Ouchi N, Parker JL, Lugus JJ, Walsh K, (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11: 85-97.
35. Deng Y, Scherer PE, (2010) Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 1212: E1-E19.
36. Brown R, Imran SA, Belsham DD, Ur E, Wilkinson M, (2007) Adipokine gene expression in a novel hypothalamic neuronal cell line: resistin-dependent regulation of fasting-induced adipose factor and SOCS-3. Neuroendocrinology 85: 232-241.
37. Wilkinson M, Brown R, Imran SA, Ur E, (2007) Adipokine gene expression in brain and pituitary gland. Neuroendocrinology 86: 191-209.
38. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, et al. (1996) Abnormal splicing of the leptin receptor in diabetic mice. Nature 379: 632-635.
39. Fei H, Okano HJ, Li C, Lee GH, Zhao C, et al. (1997) Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci U S A 94: 7001-7005.
40. Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB, (1998) Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 395: 535-547.
41. Thaler JP, Schwartz MW, (2010) Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology 151: 4109-4115.
42. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS, (2010) Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 152: 93-100.
43. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, et al. (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382: 250-252.
44. Ahima RS, Saper CB, Flier JS, Elmquist JK, (2000) Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 21: 263-307.
45. Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS, (2003) The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 111: 1409-1421.
46. Chan JL, Williams CJ, Raciti P, Blakeman J, Kelesidis T, et al. (2008) Leptin does not mediate short-term fasting-induced changes in growth hormone pulsatility but increases IGF-I in leptin deficiency states. J Clin Endocrinol Metab 93: 2819-2827.
47. Howard JK, Flier JS, (2006) Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab 17: 365-371.
48. Myers MG, Cowley MA, Munzberg H, (2008) Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70: 537-556.
49. Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS, (1998) Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1: 619-625.
50. Myers MG Jr, (2004) Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 59: 287-304.
51. Hosoi T, Sasaki M, Miyahara T, Hashimoto C, Matsuo S, et al. (2008) Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol 74: 1610-1619.
52. Zhang X, Zhang G, Zhang H, Karin M, Bai H, et al. (2008) Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell 135: 61-73.
53. Milanski M, Degasperi G, Coope A, Morari J, Denis R, et al. (2009) Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci 29: 359-370.
54. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, et al. (2009) Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 9: 35-51.
55. Cnop M, Foufelle F, Velloso LA, (2012) Endoplasmic reticulum stress, obesity and diabetes. Trends Mol Med 18: 59-68.
56. Ron D, Walter P, (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529.
57. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, et al. (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306: 457-461.
58. Scheuner D, Vander Mierde D, Song B, Flamez D, Creemers JW, et al. (2005) Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis. Nat Med 11: 757-764.
59. Hof PR YW, Bloom FE, Belichenko PB, Cello MR, (2000) Comparative cytoarchitectonic atlas of the C57BL/6 and 129/Sv mouse brains. Amsterdam: Elsevier.
60. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, et al. (2001) Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411: 480-484.
61. Barsh GS, Schwartz MW, (2002) Genetic approaches to studying energy balance: perception and integration. Nat Rev Genet 3: 589-600.
62. Grill HJ, (2010) Leptin and the systems neuroscience of meal size control. Front Neuroendocrinol 31: 61-78.
63. Groah SL, Nash MS, Ward EA, Libin A, Mendez AJ, et al. (2011) Cardiometabolic risk in community-dwelling persons with chronic spinal cord injury. J Cardiopulm Rehabil Prev 31: 73-80.
64. Valentine RJ, McAuley E, Vieira VJ, Baynard T, Hu L, et al. (2009) Sex differences in the relationship between obesity, C-reactive protein, physical activity, depression, sleep quality and fatigue in older adults. Brain Behav Immun 23: 643-648.
65. Valentine RJ, Vieira VJ, Woods JA, Evans EM, (2009) Stronger relationship between central adiposity and C-reactive protein in older women than men. Menopause 16: 84-89.
66. Demirel S, Demirel G, Tukek T, Erk O, Yilmaz H, (2001) Risk factors for coronary heart disease in patients with spinal cord injury in Turkey. Spinal Cord 39: 134-138.
67. Groah SaKM, (2010) The state of aging and public health for people with spinal cord injury: Lost in transition? Top Spinal Cord Inj Rehabil 15: 1-10.
68. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, et al. (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324: 1149-1155.
69. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, et al. (1992) A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268: 877-881.
70. Bauman WA, Adkins RH, Spungen AM, Waters RL, Kemp B, et al. (2001) Levels of plasma homocysteine in persons with spinal cord injury. J Spinal Cord Med 24: 81-86.
71. Liang H CD, Wang Y, Rimmer JH, Braunschweig CL, (2007) Different risk factor patterns for metabolic syndrome in men with spinal cord injury compared to able-bodied men despite similar prevalence rates. Arch Phys Med Rehabil 88: 1198-1204.
72. Wang TD WY, Hung TS, Su TC, Pan SL, Chen SY, (2007) Circulating levels of markers of inflammation and endothelial activation are increased in men with chronic spinal cord injury. J Formos Med Assoc 106: 919-928.
73. Groah SL, Weitzenkamp D, Sett P, Soni B, Savic G, (2001) The relationship between neurological level of injury and symptomatic cardiovascular disease risk in the aging spinal injured. Spinal Cord 39: 310-317.
74. Rosado-Rivera D, Radulovic M, Handrakis JP, Cirnigliaro CM, Jensen AM, et al. (2011) Comparison of 24-hour cardiovascular and autonomic function in paraplegia, tetraplegia, and control groups: implications for cardiovascular risk. J Spinal Cord Med 34: 395-403.
75. Teasell RW, Arnold JM, Krassioukov A, Delaney GA, (2000) Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury. Arch Phys Med Rehabil 81: 506-516.
76. Verberne AJ, Lam W, Owens NC, Sartor D, (1997) Supramedullary modulation of sympathetic vasomotor function. Clin Exp Pharmacol Physiol 24: 748-754.
77. Verberne AJ, Owens NC, (1998) Cortical modulation of the cardiovascular system. Prog Neurobiol 54: 149-168.
78. Dampney RA, Coleman MJ, Fontes MA, Hirooka Y, Horiuchi J, et al. (2002) Central mechanisms underlying short- and long-term regulation of the cardiovascular system. Clin Exp Pharmacol Physiol 29: 261-268.
79. Grigorean VT, Sandu AM, Popescu M, Iacobini MA, Stoian R, et al. (2009) Cardiac dysfunctions following spinal cord injury. J Med Life 2: 133-145.
80. Tsitouras PD, Zhong YG, Spungen AM, Bauman WA, (1995) Serum testosterone and growth hormone/insulin-like growth factor-I in adults with spinal cord injury. Horm Metab Res 27: 287-292.
81. Wang YH, Huang TS, Lien IN, (1992) Hormone changes in men with spinal cord injuries. Am J Phys Med Rehabil 71: 328-332.
82. Shetty KR, Sutton CH, Mattson DE, Rudman D, (1993) Hyposomatomedinemia in quadriplegic men. Am J Med Sci 305: 95-100.
83. Cheville AL, Kirshblum SC, (1995) Thyroid hormone changes in chronic spinal cord injury. J Spinal Cord Med 18: 227-232.
84. Lavela SL, Weaver FM, Goldstein B, Chen K, Miskevics S, et al. (2006) Diabetes mellitus in individuals with spinal cord injury or disorder. J Spinal Cord Med 29: 387-395.
85. Wilkinson M, Wilkinson D, Wiesner G, Morash B, Ur E, (2005) Hypothalamic resistin immunoreactivity is reduced by obesity in the mouse: co-localization with alpha-melanostimulating hormone. Neuroendocrinology 81: 19-30.
86. Brown R, Thompson HJ, Imran SA, Ur E, Wilkinson M, (2008) Traumatic brain injury induces adipokine gene expression in rat brain. Neurosci Lett 432: 73-78.
87. Wiesner G, Brown RE, Robertson GS, Imran SA, Ur E, et al. (2006) Increased expression of the adipokine genes resistin and fasting-induced adipose factor in hypoxic/ischaemic mouse brain. Neuroreport 17: 1195-1198.
88. Kim HK, Youn BS, Shin MS, Namkoong C, Park KH, et al. (2010) Hypothalamic Angptl4/Fiaf is a novel regulator of food intake and body weight. Diabetes 59: 2772-2780.
89. Belanger AJ, Lu H, Date T, Liu LX, Vincent KA, et al. (2002) Hypoxia up-regulates expression of peroxisome proliferator-activated receptor gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1alpha. J Mol Cell Cardiol 34: 765-774.
90. Koster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, et al. (2005) Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146: 4943-4950.
91. Mandard S, Zandbergen F, van Straten E, Wahli W, Kuipers F, et al. (2006) The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem 281: 934-944.
92. Xu A, Lam MC, Chan KW, Wang Y, Zhang J, et al. (2005) Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci U S A 102: 6086-6091.
93. Wiesner G, Morash BA, Ur E, Wilkinson M, (2004) Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus. J Endocrinol 180: R1-6.
94. Brown R, Imran SA, Wilkinson M, (2009) Lipopolysaccharide (LPS) stimulates adipokine and socs3 gene expression in mouse brain and pituitary gland in vivo, and in N-1 hypothalamic neurons in vitro. J Neuroimmunol 209: 96-103.
95. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, et al. (2001) The hormone resistin links obesity to diabetes. Nature 409: 307-312.
96. Rajala MW, Obici S, Scherer PE, Rossetti L, (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111: 225-230.
97. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA, (2005) Activation of SOCS-3 by resistin. Mol Cell Biol 25: 1569-1575.
98. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, et al. (2005) The potential role of resistin in atherogenesis. Atherosclerosis 182: 241-248.
99. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A, (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27: 2450-2457.
100. Koyanagi I, Iwasaki Y, Hida K, Akino M, Imamura H, et al. (2000) Acute cervical cord injury without fracture or dislocation of the spinal column. J Neurosurg 93: 15-20.
101. Sekhon LH, Fehlings MG, (2001) Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976) 26: S2-12.
102. Robertson SA, Leinninger GM, Myers MG Jr, (2008) Molecular and neural mediators of leptin action. Physiol Behav 94: 637-642.
103. Kelesidis T, Daikos G, Boumpas D, Tsiodras S, (2011) Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15: e2-16.
104. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, et al. (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269: 540-543.
105. White DW, Tartaglia LA, (1996) Leptin and OB-R: body weight regulation by a cytokine receptor. Cytokine Growth Factor Rev 7: 303-309.
106. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, et al. (1997) Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387: 903-908.
107. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, et al. (2007) Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 356: 237-247.
108. Oswal A, Yeo G, (2010) Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity. Obesity (Silver Spring) 18: 221-229.
109. Friedman JM, Halaas JL, (1998) Leptin and the regulation of body weight in mammals. Nature 395: 763-770.
110. Harris RB, Zhou J, Youngblood BD, Rybkin, II, Smagin GN, et al. (1998) Effect of repeated stress on body weight and body composition of rats fed low- and high-fat diets. Am J Physiol 275: R1928-1938.
111. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, et al. (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110: 1093-1103.
112. Koerner A, Kratzsch J, Kiess W, (2005) Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 19: 525-546.
113. Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, et al. (2002) Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 106: 1919-1924.
114. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, et al. (2001) Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 25: 805-810.
115. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, et al. (2004) Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 89: 3872-3878.
116. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, et al. (2004) Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 44: 1819-1824.
117. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, et al. (2000) Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 36: 501-505.
118. Atkinson LL, Fischer MA, Lopaschuk GD, (2002) Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 277: 29424-29430.
119. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM, (2003) Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108: 754-759.
120. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, et al. (2004) Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53: 2366-2374.
121. Sloan C, Tuinei J, Nemetz K, Frandsen J, Soto J, et al. (2011) Central leptin signaling is required to normalize myocardial fatty acid oxidation rates in caloric-restricted ob/ob mice. Diabetes 60: 1424-1434.
122. Yoshida H, Matsui T, Hosokawa N, Kaufman RJ, Nagata K, et al. (2003) A time-dependent phase shift in the mammalian unfolded protein response. Dev Cell 4: 265-271.
123. Harding HP, Calfon M, Urano F, Novoa I, Ron D, (2002) Transcriptional and translational control in the Mammalian unfolded protein response. Annu Rev Cell Dev Biol 18: 575-599.
124. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, et al. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313: 1137-1140.